Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity Trial of MPV/S-2P Booster Vaccine in Previously Vaccinated Adults
NCT06441968Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MPV/S-2P in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of abnormal clinical safety laboratory AEs at Day 8, Frequency of solicited local adverse events (AEs) and 10 more. Started Jul 2024; status: completed.
02
Drugs
MPV/S-2P
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06441968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441968.